Found: 2
Select item for more details and to access through your institution.
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 12, p. 3573, doi. 10.1111/bcp.15854
- By:
- Publication type:
- Article
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair.
- Published in:
- Frontiers in Molecular Neuroscience, 2024, p. 1, doi. 10.3389/fnmol.2024.1411384
- By:
- Publication type:
- Article